138 related articles for article (PubMed ID: 31971174)
1. An octopus-mimic PEGylated peptide as a specific integrin αvβ3 inhibitor for preventing tumor progression.
Shan X; Zhang L; Xu Y; Sun L; Guo L; Feng S; Ge H; Gu T; Ning X
Chem Commun (Camb); 2020 Feb; 56(14):2178-2181. PubMed ID: 31971174
[TBL] [Abstract][Full Text] [Related]
2. Smart pH-Sensitive Nanogels for Enhancing Synergistic Anticancer Effects of Integrin α
Xu Y; Sun L; Feng S; Chen J; Gao Y; Guo L; An X; Nie Y; Zhang Y; Liu X; Ning X
ACS Appl Mater Interfaces; 2019 Sep; 11(38):34663-34675. PubMed ID: 31490654
[TBL] [Abstract][Full Text] [Related]
3. β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate.
López Rivas P; Müller C; Breunig C; Hechler T; Pahl A; Arosio D; Belvisi L; Pignataro L; Dal Corso A; Gennari C
Org Biomol Chem; 2019 May; 17(19):4705-4710. PubMed ID: 31020985
[TBL] [Abstract][Full Text] [Related]
4. Targeted MMP-2 responsive chimeric polymersomes for therapy against colorectal cancer.
Ramezani P; Abnous K; Taghdisi SM; Zahiri M; Ramezani M; Alibolandi M
Colloids Surf B Biointerfaces; 2020 Sep; 193():111135. PubMed ID: 32447200
[TBL] [Abstract][Full Text] [Related]
5. Discovery of dual targeting PEGylated BG-P
Ozen Karakus O; Godugu K; Mousa SA
Bioorg Med Chem; 2021 Aug; 43():116278. PubMed ID: 34157571
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
7. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
[TBL] [Abstract][Full Text] [Related]
8. An integrin αvβ3 antagonistic modified peptide inhibits tumor growth through inhibition of the ERK and AKT signaling pathways.
Hu L; Wang J; Wang Y; Xu H
Oncol Rep; 2016 Oct; 36(4):1953-62. PubMed ID: 27499314
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
10. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
11. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.
Dayam R; Aiello F; Deng J; Wu Y; Garofalo A; Chen X; Neamati N
J Med Chem; 2006 Jul; 49(15):4526-34. PubMed ID: 16854058
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of oleandrin derivatives and their cytotoxic activity.
Zhang Y; Chen X; Zhou Y; Hou J; Long H; Zhang Z; Lei M; Wu W
Steroids; 2020 Jul; 159():108650. PubMed ID: 32360418
[TBL] [Abstract][Full Text] [Related]
13. Two birds, one stone: dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12.
Sun W; Li L; Li LJ; Yang QQ; Zhang ZR; Huang Y
Acta Pharmacol Sin; 2017 Jun; 38(6):806-822. PubMed ID: 28065935
[TBL] [Abstract][Full Text] [Related]
14. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.
Huang YQ; Yuan JD; Ding HF; Song YS; Qian G; Wang JL; Ji M; Zhang Y
Eur J Med Chem; 2018 Oct; 158():82-90. PubMed ID: 30199708
[TBL] [Abstract][Full Text] [Related]
16. Polymeric Thioxanthones as Potential Anticancer and Radiotherapy Agents.
Yilmaz G; Guler E; Barlas FB; Timur S; Yagci Y
Macromol Rapid Commun; 2016 Jul; 37(13):1046-51. PubMed ID: 27168378
[TBL] [Abstract][Full Text] [Related]
17. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
18. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models.
Zhu T; Gu J; Yu K; Lucas J; Cai P; Tsao R; Gong Y; Li F; Chaudhary I; Desai P; Ruppen M; Fawzi M; Gibbons J; Ayral-Kaloustian S; Skotnicki J; Mansour T; Zask A
J Med Chem; 2006 Feb; 49(4):1373-8. PubMed ID: 16480272
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
Perez HL; Chaudhry C; Emanuel SL; Fanslau C; Fargnoli J; Gan J; Kim KS; Lei M; Naglich JG; Traeger SC; Vuppugalla R; Wei DD; Vite GD; Talbott RL; Borzilleri RM
J Med Chem; 2015 Feb; 58(3):1556-62. PubMed ID: 25584393
[TBL] [Abstract][Full Text] [Related]
20. BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.
Shan W; Balog A; Quesnelle C; Gill P; Han WC; Norris D; Mandal S; Thiruvenkadam R; Gona KB; Thiyagarajan K; Kandula S; McGlinchey K; Menard K; Wen ML; Rose A; White R; Guarino V; Shen DR; Cvijic ME; Ranasinghe A; Dai J; Zhang Y; Wu DR; Mathur A; Rampulla R; Trainor G; Hunt JT; Vite GD; Westhouse R; Lee FY; Gavai AV
Bioorg Med Chem Lett; 2015 May; 25(9):1905-9. PubMed ID: 25857941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
